EN
ENDO.US Endocan Corp
- Market cap
- USD 58.8K
- P/E
- -
- P/B
- 12.18x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2013.
Is ENDO.US undervalued?
Graham numberThe Graham number of Endocan Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Endocan Corp fundamental analysis
No fundamental analysis for Endocan Corp yet.
Endocan Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Endocan Corp
Thermic Sciences International develops and sells hemp based products. The company offers hemp formulation-based health and wellness solutions, as well as cosmeceuticals, nutraceuticals, and food brands. It also provides over the counter products for hair and skin include Hempery miracle oil, a skin care solution; Hemp milk body wash, a creamy soap; Hemp lotion bars for moisturizing hands and body; Hemp rose soap; and Hemtastique lip and body balms. The company also develops…
Full company profileEndocan Corp financial statements
2013 annualized: Fiscal year 2013 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2013, the balance sheet is the latest quarter. Figures change when the annual report is published.
Endocan Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 37.4K | 414K | 1.13M | 1.63M | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | 8.25K | 255K | 821K | 1.63M | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -7.90K | -15.5K | -506K | -1.94M | -2.62M | -25.8K | -40.9K | -127K | -111K | -743K | -2.06M |
| EBITDA | -7.90K | -15.5K | -494K | -1.92M | -2.60M | -1.15M | 424K | -127K | -111K | -743K | -3.26M |
| Net Income | -7.90K | -73.8K | -364K | -2.12M | -3.20M | -3.11M | -353K | -5.30M | -1.98M | -3.31M | -13.8M |
| EPS | -0.01 | -0.06 | -0.35 | -1.55 | -2.11 | -1.43 | -0.07 | -0.83 | -0.11 | -0.10 | -0.37 |
| Balance Sheet | |||||||||||
| Total Assets | - | 41.8K | 57.9K | 483K | 1.52M | 933K | 9.08K | 571K | - | 359.00 | 59.00 |
| Total Liabilities | 926.00 | 42.3K | 270K | 1.36M | 1.17M | 1.64M | 1.07M | 1.18M | 1.24M | 1.50M | 1.49M |
| Shareholders' Equity | -926.00 | -512.00 | -213K | -876K | 350K | -712K | -1.06M | -607K | -1.24M | -1.50M | -1.49M |
| Cash & Short-term Investments | - | 4.90K | 10.5K | 1.96K | 740K | 18.5K | 1.08K | - | - | 359.00 | 59.00 |
| Total Debt | - | - | 156K | 930K | 643K | 1.64M | 250K | 286K | 285K | 272K | 272K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -6.98K | 36.7K | -74.4K | -622K | -2.08M | -406K | -73.1K | -124K | -77.1K | -106K | -91.7K |
| Capital Expenditure | 0.00 | 0.00 | 43.6K | 58.4K | 5.64K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -6.98K | 36.7K | -118K | -680K | -2.09M | -406K | -73.1K | -124K | -77.1K | -106K | -91.7K |
| Ratios | |||||||||||
| ROE | - | - | - | - | -915.5% | - | - | - | - | - | - |
| ROA | - | -176.7% | -628.9% | -439.0% | -210.2% | -333.7% | -3,887.2% | -928.5% | - | -922,391.1% | -23,335,593.2% |
| Net Profit Margin | - | -197.2% | -87.9% | -187.8% | -196.7% | - | - | - | - | - | - |
| Debt to Equity | - | - | - | - | 1.84x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Endocan Corp dividends
Endocan Corp has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Aug 9, 2010.
Who owns Endocan Corp
Ownership data of Endocan Corp is not available yet.
Endocan Corp company profile
- Company name
- Endocan Corp
- Ticker
- ENDO.US
- Exchange
- USA Stocks
- Sector
- Basic Materials
- Industry
- Chemicals
- Fiscal year end
- December
- Address
- 2910 North Powers Boulevard, Colorado Springs, CO, United States, 80922
- Phone
- 888 263 0490
- Website
- omnicanna.com
About Endocan Corp
Thermic Sciences International develops and sells hemp based products. The company offers hemp formulation-based health and wellness solutions, as well as cosmeceuticals, nutraceuticals, and food brands. It also provides over the counter products for hair and skin include Hempery miracle oil, a skin care solution; Hemp milk body wash, a creamy soap; Hemp lotion bars for moisturizing hands and body; Hemp rose soap; and Hemtastique lip and body balms. The company also develops products for ailments, such as acquired immune deficiency syndrome/human immunodeficiency virus, asthma, cancer, glaucoma, influenza, pain management, and post-traumatic stress disorder. It distributes its products in the United States, Canada, Colombia, Ireland, India, China, Japan, South Korea, and Afghanistan through online and in retail stores. The company was incorporated in 1969 and is based in Colorado Springs, Colorado.
Endocan Corp management
7- Mr. Raymond C. DabneyPresident & CEO · born 1965
- Mr. Robert James KaneCFO & Director · born 1976
- Mr. Anthony SpringHead of Technology Development & Director
- Ms. Graciela MorenoSenior VP & Director
- Mr. Alfredo Dupetit-BernardiVP of European Operations & Director · born 1962
- Mr. Wayne HoweyHead of Food Services
- Mr. C. K. TamTreasurer, Secretary & Director · born 1959